This chapter integrates findings on CSNPs as a novel nanoplatform for addressing brucellosis, highlighting essential conclusions, ongoing challenges, and prospective avenues for future research. CSNPs, characterized by their biocompatibility, cohesiveness, antimicrobial properties, and encapsulation capacity, represent a promising approach for targeted and sustained delivery against intracellular Brucella spp. Various challenges persist, including stability, accurate targeting of macrophages, enhancement of intracellular delivery to phagolysosomal compartments, and necessity for synthesis process that is scalable and reproducible in accordance with regulatory standards. The upcoming environment encompasses the engineering of functionalized CSNPs employing ligand-mediated targeting, the development of stimuli-responsive release systems, the formulation of immunomodulatory agents, and the establishment of hybrid nanocomposites, all aimed at improving therapeutic efficiency and addressing the challenge of antibiotic resistance. Advancements in in vivo imaging, nanotoxicology, and clinical nanomedicine will significantly improve the development of next-generation chitosan-based nanotherapeutics for the efficient management of brucellosis.